ArticleMethods in molecular biology (Clifton, N.J.)2025
Bioinformatic Analysis of Alzheimer's Disease Metabolomic Datasets for Ceramides and Gangliosides.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is a significant neurodegenerative condition that adversely affects memory, cognition, and motor function. It involved multiple pathologies, with amyloid beta and tau proteins playing crucial roles. Prior to observable cognitive decline, alterations in neuronal cells contribute to disease progression. Sphingomyelin, found in lipid rafts and myelin sheaths, regulates CNS cell growth, differentiation, and apoptosis. Dysregulation in sphingolipid metabolism may impact early AD stages. Ceramides, derived from sphingomyelin hydrolysis, play a role in amyloid beta-related neurodegeneration. Gangliosides, abundant in human brains, interact with cholesterol and other lipids in lipid rafts. Ongoing studies explore GM1, a type of ganglioside, and its relationship with amyloid beta aggregation, potentially influencing AD pathogenesis.Researchers can investigate lipid differences between AD and control brain samples by conducting a meta-analysis on proteomic databases, focusing on gangliosides and ceramides. Analyzing data by brain region may reveal specific dysregulated lipids and proteins in AD brains. In this book chapter, we discuss the processing of raw data sets through MS-DIAL.
Indexed as
Identifiers
40498204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.